|
Published:
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry ConferenceSAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc.
(Nasdaq: CADX), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally for
use in the hospital setting, announced today that the company's President and
CEO The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days. About Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.
Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence
Pharmaceuticals, Inc.
Contacts:
William R. LaRue Anna Gralinska
SVP & Chief Financial Officer Director, Investor Relations
Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.
858-436-1400 858-436-1452
SOURCE Cadence Pharmaceuticals, Inc. Tags: ,HEA,MTC,BIO,TDS,CCA,CA-Cadence-Newsmakers _ _     Is your favorite bookmark site missing? Ask for it. |
|
